marked.bio

Company

TYK Medicines

4 active trials that select patients by a biomarker on marked.bio; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

TY-9591 3osimertinib 2

Trials

4 of 8 trials shown

  1. Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

    Recruiting Phase 3 TYK Medicines Started 2022Primary completion 2025-05 NCT05382728

    TY-9591osimertinib FDA EU

    Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites)…

    EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2024-01-30NSCLC, EGFR Activating Mutation

  2. A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

    Not yet recruiting Phase 2 TYK Medicines Started 2025Primary completion 2027-12 NCT06672068

    TY-9591pemetrexedcisplatincarboplatin

    Tissue or blood samples tested positive for EGFR sensitive mutations (including exon 19 deletion, exon 21 L858R mutation, alone or in combination with other EGFR mutations) by central la…

    EGFR exon 19 deletion / L858RNSCLC

  3. TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

    Recruiting Phase 2 TYK Medicines Started 2023Primary completion 2025-12 NCT05948813

    TY-9591osimertinib FDA EU

    Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites)…

    EGFR exon 19 deletion / L858RNSCLC, EGFR Activating Mutation, Brain Metastases

  4. A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors

    Recruiting Phase 1 TYK Medicines Started 2023Primary completion 2025-10 NCT05866692

    TY-2699a

    …n cancer, small cell lung cancer, castrate-resistant prostate cancer (CRPC), or PDAC with KRAS mutant

    KRAS G12CKRAS G12DStatus may be outdated, last updated 2023-11-07Solid Tumor, Adult